GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyprotex PLC (LSE:CRX) » Definitions » Total Receivables

Cyprotex (LSE:CRX) Total Receivables : £2.53 Mil (As of Jun. 2016)


View and export this data going back to 2002. Start your Free Trial

What is Cyprotex Total Receivables?

Cyprotex's Total Receivables for the quarter that ended in Jun. 2016 was £2.53 Mil.


Cyprotex Total Receivables Historical Data

The historical data trend for Cyprotex's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyprotex Total Receivables Chart

Cyprotex Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 1.20 1.50 2.05 3.02

Cyprotex Semi-Annual Data
Dec06 Jun07 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 2.05 2.17 3.02 2.53

Cyprotex Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Cyprotex Total Receivables Related Terms

Thank you for viewing the detailed overview of Cyprotex's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyprotex (LSE:CRX) Business Description

Traded in Other Exchanges
N/A
Address
Cyprotex PLC was incorporated on October 25, 2001. The Company together with its subsidiaries, provides in vitro and in silico ADMET and PK (absorption, distribution, metabolism, excretion, toxicity and pharmacokinetics) information to a number of different industries including the Pharmaceutical, Biotechnology, Cosmetic, Personal Care, Agrochemical, Chemical Industries and Academia. It provides a range of ADME Tox contract research services, which includes ADME screening, Customized ADME assays, Genomic ADME, In silico pharmacokinetics modeling and In vitro toxicology. It also offers integrated drug discovery services in collaboration with Sygnature Discovery and physicochemical profiling services in collaboration with Sirius Analytical. The Company operates in North America, Mainland Europe and United Kingdom.

Cyprotex (LSE:CRX) Headlines

No Headlines